StockNews.com Initiates Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

Investment analysts at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

EGRX stock opened at $0.50 on Tuesday. The stock has a 50-day moving average price of $2.59 and a 200-day moving average price of $3.89. Eagle Pharmaceuticals has a 1-year low of $0.00 and a 1-year high of $14.40.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of EGRX. Perceptive Advisors LLC acquired a new position in Eagle Pharmaceuticals during the 2nd quarter worth approximately $971,000. Vanguard Group Inc. raised its position in shares of Eagle Pharmaceuticals by 0.4% during the first quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock worth $3,358,000 after purchasing an additional 2,630 shares during the period. Price T Rowe Associates Inc. MD bought a new position in shares of Eagle Pharmaceuticals in the 1st quarter worth $83,000. Fidelis Capital Partners LLC bought a new position in shares of Eagle Pharmaceuticals in the 2nd quarter worth $71,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in Eagle Pharmaceuticals in the 2nd quarter valued at $76,000. Institutional investors and hedge funds own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.